CagriSema vs Mounjaro results — 7 critical facts.

CagriSema vs Mounjaro results finally have a real, head-to-head answer following the REDEFINE 4 trial announced in February 2026 — and the honest verdict is more nuanced than the “CagriSema failed” headlines suggested. Both produced more than 20% average weight loss. Mounjaro won. But the story doesn’t end there.

This guide breaks down exactly what the CagriSema vs Mounjaro results showed, why the mechanisms differ, where availability stands right now, and what this genuinely means for anyone choosing between current and future treatment options. For a broader overview, read our full guide on CagriSema vs Mounjaro. General treatment information is available through the NHS.

CagriSema vs Mounjaro Results — fact 1: what REDEFINE 4 showed

The REDEFINE 4 trial was the first direct phase 3 head-to-head comparison of CagriSema against Mounjaro (tirzepatide) in adults with obesity. Over 84 weeks, CagriSema produced an average of 20.2% body weight loss in the treatment-policy analysis — which counts all participants including those who stopped — compared to 23.6% for Mounjaro at its 15mg maximum dose.

The trial was designed specifically to demonstrate that CagriSema was at least as effective as Mounjaro — what statisticians call non-inferiority. It did not meet that goal. The difference was statistically significant, meaning Mounjaro’s advantage was not due to chance. When looking only at participants who completed the full course, the figures were 23.0% for CagriSema versus 25.5% for Mounjaro — a similar margin.

CagriSema vs Mounjaro Results — fact 2: the important nuance

The CagriSema vs Mounjaro results story deserves more nuance than the “CagriSema failed” headlines provided. A 20.2% average weight loss across an entire trial population including dropouts is genuinely remarkable — it exceeds what standard-dose Wegovy achieves, and it places CagriSema firmly among the most effective weight loss compounds ever tested.

What CagriSema failed to do was match Mounjaro — a meaningfully higher bar than simply being effective. The trial was specifically designed to prove equivalence to what is currently the best-performing approved weight loss medication, and on that specific goal, it fell short. But “didn’t beat Mounjaro” and “doesn’t work well” are very different conclusions.

CagriSema vs Mounjaro Results — fact 3: different mechanisms

The CagriSema vs Mounjaro results reflect a genuine mechanistic difference between the two compounds, not just a dose or formulation issue. Mounjaro activates both GIP and GLP-1 receptors simultaneously — a dual incretin approach. CagriSema combines semaglutide (a GLP-1 agonist) with cagrilintide (an amylin analogue), which works through a completely separate hormonal pathway than GIP.

Both are dual-mechanism approaches, but through different biological routes. This distinction is clinically meaningful: patients who respond less strongly to GIP-based approaches may theoretically respond differently to amylin-based combinations. Population averages from a trial don’t capture individual variation, which is precisely why having multiple effective options with different mechanisms has genuine value even when one consistently wins on average results.

The amylin pathway that cagrilintide targets is particularly interesting because amylin acts on different brain regions than GLP-1 or GIP — specifically areas involved in satiety signalling and gastric motility. This means CagriSema essentially targets appetite through two distinct neurological routes simultaneously, which is theoretically complementary rather than redundant, even though the REDEFINE 4 CagriSema vs Mounjaro results suggest the GIP plus GLP-1 approach remains superior in aggregate.

CagriSema vs Mounjaro Results — fact 4: CagriSema vs Wegovy

To understand where CagriSema sits in the broader landscape, the REDEFINE 1 trial provides essential context. In that study, CagriSema produced 22.7% weight loss compared to 14.9% for semaglutide alone — the active ingredient in Wegovy — over 68 weeks. That’s a difference of nearly 8 percentage points in favour of CagriSema over standard-dose Wegovy.

The picture is more complex with the newer 7.2mg Wegovy dose approved in January 2026, which produced 20.7% weight loss in the STEP UP trial — much closer to CagriSema’s 22.7% in REDEFINE 1. CagriSema and the higher-dose Wegovy haven’t been directly compared yet, making the relative positioning between them genuinely uncertain at this stage.

CagriSema vs Mounjaro Results — fact 5: the availability gap

The most practically important CagriSema vs Mounjaro results difference isn’t efficacy — it’s availability. Mounjaro has been licensed in the UK since November 2023 and in the EU since 2022. It is available today through registered prescribers, with established supply chains and pricing.

CagriSema, by contrast, is not approved anywhere in the world as of September 2026. Novo Nordisk has filed an NDA in the United States, but no confirmed approval timeline has been announced and no UK submission has been confirmed. Realistic availability in the UK or Ireland, even in an optimistic scenario, remains at least 2-3 years away.

CagriSema vs Mounjaro Results — fact 6: side effect differences

Both Mounjaro and CagriSema share the gastrointestinal side effect profile common to the GLP-1 class — nausea, vomiting, diarrhoea, and constipation are reported with both. However, CagriSema showed a higher rate of nausea and vomiting in trials compared to Mounjaro, possibly related to the added cagrilintide component.

Discontinuation rates due to adverse events were also higher with CagriSema in REDEFINE 4 than with Mounjaro — a contributing factor to the difference in the treatment-policy analysis (all participants) versus the completer-only analysis. For those who did complete the full CagriSema course, results were considerably stronger, which underscores how tolerability impacts real-world outcomes as much as peak efficacy.

CagriSema vs Mounjaro Results — fact 7: what comes next

Despite falling short of its REDEFINE 4 primary endpoint, CagriSema’s development continues. Novo Nordisk has other trials in the REDEFINE series still ongoing, and the US NDA submission keeps a potential approval pathway alive. The amylin-plus-GLP-1 mechanism remains scientifically interesting precisely because it differs from both Mounjaro and retatrutide, offering a genuinely distinct option for patients who may respond differently.

The CagriSema vs Mounjaro results comparison will look different in two to three years once approval decisions are made and real-world data begins accumulating. For now, Mounjaro holds every practical advantage — licensed, available, proven, and producing the strongest results of any currently approved medication.

What this means practically for anyone researching CagriSema vs Mounjaro results today is straightforward: Mounjaro is the right choice for anyone seeking the most effective currently available treatment. CagriSema is worth watching as a future option — especially for people who want an alternative mechanism to tirzepatide-based treatments — but it cannot be accessed, prescribed, or purchased anywhere right now, and that availability gap is the decisive factor for the foreseeable future.

For the full comparison including mechanism, pricing, and UK availability, read our detailed guide on CagriSema vs Mounjaro. Explore our Mounjaro product page, or read patient reviews.

The CagriSema vs Mounjaro results picture is one of the most closely watched comparisons in obesity medicine right now — and understanding what the data actually shows, rather than what the headlines said, puts you in a far stronger position to make sense of developments as they unfold over the next 12-24 months.